Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
Featured trial
  • 789 views
  • 08 Nov, 2020
  • 1 location
Featured trial
A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

A Phase III, Randomized, Double-blind, Placebo-controlled Study of Subcutaneous Secukinumab in Autoinjectors, to Demonstrate Efficacy at 24 Weeks and Long Term Safety and Efficacy up to 3.5 Years in Subjects With Active Psoriatic Arthritis

  • 2412 views
  • 23 Nov, 2020
  • 18 locations
Featured trial
A Phase 2, 12-week, double-blind, randomized, parallel group, placebo-controlled study of four doses of Study Medication in subjects with moderate to severe rheumatoid arthritis

A Phase 2, 12-week, double-blind, randomized, parallel group, placebo-controlled study of four doses of Study Medication in subjects with moderate to severe rheumatoid arthritis

  • 290 views
  • 08 Nov, 2020
  • 1 location
RA-PRO PRAGMATIC TRIAL (RA-PROPR)

medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in

glucocorticoids
DMARD
prednisone
  • 0 views
  • 28 Jun, 2022
  • 1 location
Tolerogenic Dendritic Cell Therapy for Rheumatoid Arthritis (TOLERANT)

anti-rheumatic drugs (DMARD) will be included. Any combination and dose of DMARD is allowed, with exception of Janus kinase inhibitors. Concomitant use of a low dose of prednisone (7.5 mg per day or

prednisone
antirheumatics
glucocorticoids
DMARD
remission
  • 0 views
  • 10 Mar, 2022
  • 1 location
Combination of Baricitinib and Adalimumab in Rheumatoid Arthritis (CRI-RA)

patients treated with a combination of MTX and biologic as second-line therapy. Less than 10% of patients treated with a combination of MTX and another targeted DMARD, such as baricitinib, as

tumor necrosis factor
methotrexate
tofacitinib
rituximab
adalimumab
  • 0 views
  • 15 Mar, 2022
  • 6 locations
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response

This is a 16-week, open-label study to identify factors that help predict clinical responses to DMARD therapies for RA (Rheumatoid Arthritis) patients. All patients will receive a starting dose

absolute neutrophil count
abatacept
methotrexate
steroidal anti-inflammatory drugs
rituximab
  • 14 views
  • 26 Feb, 2022
  • 1 location
Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial (SPEED)

SPEED is a three arm interventional trial nested within a cohort (Trials Within Cohorts or TWiCs design). This tests more aggressive early therapy in patients newly diagnosed with moderate to severe PsA. Arm 1 will receive standard step up therapy in the cohort and act as the control group. Arm …

tumor necrosis factor
methotrexate
adalimumab
platelet count
sulfasalazine
  • 2 views
  • 02 Jun, 2022
  • 1 location
Methotrexate and Metformin in Rheumatoid Arthritis Patients (METorMET²)

Methotrexate (MTX) is the anchor drug for patients with rheumatoid arthritis (RA). Despite its marked efficacy and acceptable side effect profile, about 1/3 of patients failed to reach RA remission. Metformin is the first-line therapy for type 2 diabetes. Its antioxidative and anti-inflammatory properties make it a good candidate for …

diabetes
methotrexate
methotrexate treatment
remission
  • 0 views
  • 18 Apr, 2022
  • 6 locations
Effects of Abatacept on Myocarditis in Rheumatoid Arthritis (AMiRA)

This study aims to evaluate the effects of abatacept, a CTLA4-Ig fusion protein that binds CD80/86 (B7-1/B7-2), on subclinical myocarditis in rheumatoid arthritis (RA) through its effect on T cell subpopulations. RA patients without clinical CVD, biologic nave, and with inadequate response to methotrexate (MTX), will undergo cardiac FDG PET/CT …

pet/ct scan
methotrexate
abatacept
adalimumab
fusion protein
  • 97 views
  • 21 Feb, 2022
  • 1 location